Severity of venous insufficiency is related to the density of microvascular deposition of PAI-1, uPA and von Willebrand factor

Vasa - Journal of Vascular Diseases

Volumn 33, Issue 1, 2004, Pages 19-24

  Kolbach, D N ^a   Hamulyak K ^a   Prins, M H ^a   Neumann, H A M ^b   Cleutjens, J P M ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Fibrinolysis; Leg ulcer; Plasminogen activator; Von Willebrand factor

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTICLE; BLOOD CLOTTING; BRIGHT FIELD MICROSCOPY; CAPILLARY; CHRONIC INFLAMMATION; CHRONIC VEIN INSUFFICIENCY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DYSTROPHY; FEMALE; FIBRINOLYSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEG ULCER; MALE; MICROCIRCULATION; PUNCH BIOPSY; SKIN BIOPSY; VEIN INSUFFICIENCY;

EID: 1542349362     PISSN: 03011526     EISSN: None     Source Type: Journal    
DOI: 10.1024/0301-1526.33.1.19     Document Type: Article

References (30)

1. Blomgren L, Johansson G, Siegbahn A, Bergqvist D. Coagulation and fibrinolysis in chronic venous insufficiency. Vasa 2001; 30: 184-7.
2. Bollinger A, Leu AJ. Evidence for microvascular thrombosis obtained by intravital fluorescence videomicroscopy. Vasa 1991; 20: 252-5.
3. Brakman M, Faber, WR, Kerckhaert JA, Kraaijenhagen RJ, Hart, HC. Immunofluorescence studies of atrophie blanche with antibodies against fibrinogen, fibrin, plasminogen activator inhibitor, factor VIII-related antigen, and collagen type IV. Vasa 1992; 21: 143-8.
4. Bugge TH, Flick MJ, Danton MJ, et al. Urokinase-type plasminogen activator is effective in fibrin clearance in the absence of its receptor or tissue-type plasminogen activator. Proc Natl Acad Sci USA 1996; 93: 5899-904.
5. Burnand KG. The aetiology of venous ulceration. Acta Chir Scand Suppl 1988; 544: 21-4.
6. Carmeliet P, Collen D. Targeted gene manipulation and transfer of the plasminogen and coagulation systems in mice. Fibrinolysis 1996; 10: 195-213.
7. Coccheri S, Scondotto G, Agnelli G, Aloisi D, Palazzini E, Zamboni V. Randomised, double blind, multicentre, placebo controlled study of sulodexide in the treatment of venous leg ulcers. Thromb Haemost 2002; 87: 947-52.
8. Coleridge Smith PD, Thomas P, Scurr JH, Dormandy JA. Causes of venous ulceration: a new hypothesis. Br Med J (Clin Res Ed) 1988; 296: 1726-7.
9. Dormandy A. Pathophysiology of venous leg ulceration. Int J Microcirc Clin Exp 1997; 17 Suppl 1: 2-5.
10. Falanga V, Eaglstein WH. The "trap" hypothesis of venous ulceration. Lancet 1993; 341: 1006-8.
11. Ferrier CM, van Geloof WL, de Witte HH, Kramer MD, Ruiter DJ, van Muijen, GN. Epitopes of components of the plasminogen activation system are re-exposed in formalin-fixed paraffin sections by different retrieval techniques. J Histochem Cytochem 1998; 46: 469-76.
12. Gibbons J. Nonparametric Measures of Association, 1993: 73-77.
13. Gschwandtner ME, Ehringer H. Microcirculation in chronic venous insufficiency. Vasc Med 2001; 6: 169-79.
14. Hafner J, Kuhne A, Schar B, et al. Factor V Leiden mutation in postthrombotic and non-postthrombotic venous ulcers. Arch Dermatol 2001; 137: 599-603.
15. Herouy Y, Aizpurua J, Stetter C, et al. The role of the urokinase-type plasminogen activator (uPA) and its receptor (CD87) in lipodermatosclerosis. J Cutan Pathol 2001; 28: 291-7.
16. Herouy Y, Hellstern MO, Vanscheidt W, Schopf E, Norgauer, J. Factor XIII-mediated inhibition of fibrinolysis and venous leg ulcers. Lancet 2000; 355: 1970-1.
17. Herouy Y, Trefzer D, Hellstern MO, et al. Plasminogen activation in venous leg ulcers. Br J Dermatol 2000; 143: 930-6.
18. Ibbotson SH, Layton AM, Davies JA, Goodfield MJ. The effect of aspirin on haemostatic activity in the treatment of chronic venous leg ulceration. Br J Dermatol 1995; 132: 422-6.
19. Kolbach DN, van Oerle R, Hamulyák K, Neumann HAM, Prins, MH. Local endothelial function and leg symptoms in patients after deep vein thrombosis. Journal of Thrombosis and Haemostasis, 2003, in press.
20. Lowe GD. Rheological influences on thrombosis. Baillieres Best Pract Res Clin Haematol 1999; 12: 435-49.
21. Mackenzie RK, Ludlam CA, Ruckley CV, Allan PL, Burns P, Bradbury AW. The prevalence of thrombophilia in patients with chronic venous leg ulceration. J Vasc Surg 2002; 35: 718-22.
22. Maessen-Visch MB, Hamulyak K, Tazelaar DJ, Crombag NH, Neumann HA. The prevalence of factor V Leiden mutation in patients with leg ulcers and venous insufficiency. Arch Dermatol 1999; 135: 41-4.
23. Margolis DJ, Kruithof EK, Barnard M, Howe K, Lazarus GS. Fibrinolytic abnormalities in two different cutaneous manifestations of venous disease. J Am Acad Dermatol 1996; 34: 204-8.
24. Nicolaides AN, Zukowski AJ. The value of dynamic venous pressure measurements. World J Surg 1986; 10: 919-24.
25. Payne SP, London NJ, Newland CJ, Thrush AJ, Barrie WW, Bell, PR. Ambulatory venous pressure: correlation with skin condition and role in identifying surgically correctible disease. Eur J Vasc Endovasc Surg 1996; 11: 195-200.
26. Peschen M, Rogers AA, Chen WY, Vanscheidt W. Modulation of urokinase-type and tissue-type plasminogen activator occurs at an early stage of progressing stages of chronic venous insufficiency. Acta Derm Venereol 2000; 80: 162-6.
27. Peschen M, Thimm C, Weyl A, et al. Possible role of coagulation factor XIII in the pathogenesis of venous leg ulcers. Vasa 1998; 27: 89-93.
28. Peschen M, Zeiske D, Laaff H, Weiss JM, Schopf E, Vanscheidt, W. Clinical histochemical and immunohistochemical investigation of the capillary basal membrane in chronic venous insufficiency. Acta Derm Venereol 1996; 76: 433-6.
29. Porter JM, Moneta GL. Reporting standards in venous disease: an update. International Consensus Committee on Chronic Venous Disease. J Vasc Surg 1995; 21: 635-45.
30. Romer J, Bugge TH, Pyke C, et al. Impaired wound healing in mice with a disrupted plasminogen gene. Nat Med 1996; 2: 287-92.